CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
Portfolio Pulse from
CASI Pharmaceuticals has dosed the first patient in its Phase 1/2 clinical trial of CID-103 for treating chronic Immune Thrombocytopenia (ITP) in China, marking a significant milestone in the drug's development.
January 06, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CASI Pharmaceuticals has initiated a Phase 1/2 trial for CID-103 in chronic ITP, marking a significant milestone in its development pipeline.
The initiation of the Phase 1/2 trial for CID-103 is a significant step forward for CASI Pharmaceuticals, potentially leading to new treatment options for chronic ITP. This development could positively impact CASI's stock price as it demonstrates progress in their drug pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100